An interventional study of Decision aid with decision analysis model and Decision aid alone in Osteoporosis, Postmenopausal, Osteoporotic Fractures and Diphosphonates, sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Enrolling by invitation at 1 site in Spain. Open to female participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Osteoporosis, Postmenopausal with a site in Spain — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis, Postmenopausal · Spain.
Among the 26 studies in Osteoporosis, Postmenopausal with a site in Spain, this one is the 18th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, and was the 26th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 26 studies in Osteoporosis, Postmenopausal with a site in Spain is open now.
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 50 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is close to the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 504 across the 25 interventional studies, 230 across the 1 observational. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 26 have an industry lead sponsor. The 10 most frequent:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 343 studies on the registry; 65 are open to participants now.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Osteoporosis, Postmenopausal with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be difficult due to potential risks and side effects.
This study will test a web-based tool designed to help women make informed decisions about fracture prevention treatment. The tool provides information about the benefits and risks of treatment. Some women in the study will also receive additional support through a decision analysis report, which helps weigh different factors when making a choice.
The study will examine whether using this tool improves decision-making, increases confidence in making a choice, and enhances satisfaction with the decision. It will also explore what factors influence women's decisions and at what level of risk they choose to start treatment.
By understanding how decision aids impact choices, researchers aim to improve the way healthcare providers support patients in making informed decisions about their health.
Open-label, randomized, open-label, multicenter, three parallel arms, controlled clinical trial. It will be carried out in primary care centers belonging to the Autonomous Communities of Madrid and Catalonia.
The participants will be recruited in the medical consultation, by their family doctor, who will assess the fulfillment of the inclusion criteria a priori and according to eligibility, will offer the woman to participate in the study, informing her about the nature of the research. The informed consent form will be signed online, and the inclusion criteria will be verified by the participant herself when accessing the tool. Participation will be voluntary and does not entail economic incentives for the participants.
Random assignment will be simple following a 1:1:1 ratio to each group. To avoid possible contamination bias, randomization will be performed at the physician level, so that each professional will be randomized to one of the intervention groups so that he/she will apply exclusively one of the study's interventions to all the participants he/she recruits. Due to the characteristics of the interventions it will not be possible to blind the interveners and participants. After randomization, only the data analysts will be blinded to the randomization sequence. The central research team will primarily contact participants via email to send the decision aid tool link and questionnaire links. They will also follow up to ensure the completion of all data provided by the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will use DASH-Osteo decision aid plus the information in plain language, provided by a decision analysis model which will include the utilities provided by the same participants in the web- based tool, and will make a shared decision with their healthcare professional.
Other: Decision aid with decision analysis model
Participants in this group will use DASH-osteo decision and will make a shared decision with their healthcare professional.
Other: Decision aid alone
Participants in this group will make a decision according to centre's usual practice
Other: Usual Care
Women will use the web version of the decision aid tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by their central research team via e-mail. Each woman is expected to use the web tool and select her preferences (utilities) regarding different health conditions (e.g. hip fracture). The results of the exercises will be received automatically at the central level (by institutional e-mail to the researcher responsible for the data a PDF file will be sent from the web). The research team at the central level will apply the decision analysis model, using information on the baseline fracture risk and preferences of each participant entered into the tool. The results of the decision analysis model will be delivered to the women directly by e-mail in plain language, so that they can make the final decision together with their general practitioner in a second visit.
Participants will use the web tool. They will have a supporting video to help them how to navigate the tool during. They will be able to access the tool through a specific link that will be shared with them by the central research team via e-mail. Each woman is expected to navigate through the different functions of the web tool, at home or at a time other than the medical visit, and select her preferences (utilities) with respect to different health conditions (e.g. hip fracture). The women in this group would decide whether or not to take the pharmacological treatment based on the information provided by the tool but without the results of the decision analysis model described for the intervention group. Subsequently, those who wished to do so would make a final decision together with their physician at a second visit.
Women in this group will receive standard clinical practice, without the use of the shared decision support tool or the decision analysis model or any other support. At the end of the visit, their physician will provide them with a link to access the assessment questionnaires.
Also known as: Usual practice
Decisional conflict
We will use the Decisional conflict scale (O'Connor 1998, updated 2010), to evaluate the uncertainty and the decision-making conflict across participants. It is a 16-item scale. IItems are summed, then multiplied by 25. Scoring goes from 0 (low decisional conflict) to 100 (high decisional conflict). Patients with a total score \>38 tend to delay decisions, whereas those with ≤ 25 tend to make decisions(1, 2) 1. O'Connor AM. Validation of a Decisional Conflict Scale. Med Decis Making \[Internet\]. 1995 Feb;15(1):25-30. Available from: http://dx.doi.org/10.1177/0272989X9501500105 2. Bunn H, O'Connor A. Validation of Client Decision-Making Instruments in the Context of Psychiatry. Can J Nurs Res \[Internet\]. 1996;28(3):13-27. Available from: https://pubmed.ncbi.nlm.nih.gov/8997937/
Time frame: Decisional conflict will be measured one time up to 26 weeks, after participant use of the web-based tool.
Decision self-efficacy
Participants, self-confidence with the decision, will be measured with the Decision Self-efficacy scale (O'Connor 1995, updated 2002) a 11-item 5-point validated scale. Items are summed, then divided by 11 and then multiplied by 25. Scores range from 0 ("extremely low self-efficacy") to 100 ("extremely high"). The scale is reliable and has been validated in different populations (1, 2). 1. Bunn H, O'Connor A. Validation of Client Decision-Making Instruments in the Context of Psychiatry. Can J Nurs Res \[Internet\]. 1996;28(3):13-27. 2. Galiana L, Sánchez-Ruiz J, Gómez-Salgado J, Larkin PJ, Sansó N. Validation of the Spanish Version of the Five-Item General Self-Efficacy (GSE) Scale in a Sample of Nursing Students: Evidence of Validity, Reliability, Longitudinal Invariance and Changes in General Self-Efficacy and Resilience in a Two-Wave Cross-Lagged Panel Model. Nurse Educ Pract \[Internet\]. 2024 Jan;74:103865.
Time frame: Decision-Self-efficacy scale will be applied, up to 26 weeks, after using the decision aid tool.
Participant satisfaction with the decision process
We will measure participants satisfaction with the decision satisfaction scale from Holmes-Rovner 1996 (SWD). SWD scale is a 6-item validated scale scoring from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate greater satisfaction with the decision (1, 2, 3 1. Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, et al. Patient Satisfaction with Health Care Decisions: The Satisfaction with Decision Scale. Med Decis Making \[Internet\]. 1996 Feb;16(1):58-64. doi.org/10.1177/0272989X9601600114 2. Wills CE, Holmes-Rovner M. Preliminary Validation of the Satisfaction With Decision scale with Depressed Primary Care Patients. Health Expect \[Internet\]. 2003 Jun;6(2):149-59. doi.org/10.1046/j.1369-6513.2003.00220.x 3. Chabrera C, Areal J, Font A, Caro M, Bonet M, Zabalegui A. Versión española de la Satisfaction With Decision scale: adaptación transcultural, validez y fiabilidad. Enferm Clin \[Internet\]. 2015 May;25(3):117-23. dx.doi.org/10.1016/j.enfcli.2015.0
Time frame: Satsfaction will be assessed up to 26 weeks, after participant's second visit with their physician.
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2025, 8 months after the start.
Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 8 months is below that.
Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau →